{"id":745055,"date":"2015-12-19T10:55:00","date_gmt":"2015-12-19T10:55:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-significantly-improves-survival-compared-to-chemotherapy-in-previously-treated-patients-with-non-small-cell-lung-cancer-whose-tumors-express-any-level-of\/"},"modified":"2025-11-07T01:24:41","modified_gmt":"2025-11-07T06:24:41","slug":"mercks-keytruda-pembrolizumab-significantly-improves-survival-compared-to-chemotherapy-in-previously-treated-patients-with-non-small-cell-lung-cancer-whose-tumors-express-any-level-of","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-significantly-improves-survival-compared-to-chemotherapy-in-previously-treated-patients-with-non-small-cell-lung-cancer-whose-tumors-express-any-level-of\/","title":{"rendered":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Significantly Improves Survival Compared to Chemotherapy in Previously-Treated Patients with Non-Small Cell Lung Cancer Whose Tumors Express Any Level of PD-L1"},"content":{"rendered":"<p class=\"bwalignc\">       KEYNOTE-010 Published in The Lancet and to be Presented at the        European Society for Medical Oncology (ESMO) Asia 2015 Congress     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced results from the pivotal KEYNOTE-010 study, the first<br \/>\n      study of its kind to evaluate the potential of an immunotherapy compared<br \/>\n      to chemotherapy based on prospective measurement of PD-L1 expression in<br \/>\n      patients with advanced non-small cell lung cancer (NSCLC). In the Phase<br \/>\n      2\/3 study, KEYTRUDA<sup>\u00ae <\/sup>(pembrolizumab), Merck\u2019s anti-PD-1<br \/>\n      (programmed death receptor-1) therapy, significantly improved overall<br \/>\n      survival (OS) compared to chemotherapy in patients with any level of<br \/>\n      PD-L1 expression, as defined by a tumor proportion score (TPS) of 1<br \/>\n      percent or more. The results were published in <i>The Lancet<\/i> and<br \/>\n      will be presented at the European Society for Medical Oncology (ESMO)<br \/>\n      Asia 2015 Congress.\n    <\/p>\n<p>\n      \u201cBecause lung cancer remains one of the most common and most challenging<br \/>\n      cancers to treat, understanding the role that KEYTRUDA can play in<br \/>\n      helping patients was essential to our development program. In this study<br \/>\n      in patients with PD-L1 expression of one percent or greater, KEYTRUDA<br \/>\n      demonstrably improved overall survival compared to chemotherapy in<br \/>\n      previously-treated patients with non-small cell lung cancer, including<br \/>\n      both squamous and non-squamous histologies,\u201d said Dr. Roger M.<br \/>\n      Perlmutter, president, Merck Research Laboratories.\n    <\/p>\n<p>\n      Merck plans to submit a supplemental Biologics License Application<br \/>\n      (sBLA) to the U.S. Food and Drug Administration for KEYTRUDA based on<br \/>\n      findings from KEYNOTE-010 by the end of 2015. The Company plans to<br \/>\n      submit a Marketing Authorization Application to the European Medicines<br \/>\n      Agency in early 2016.\n    <\/p>\n<p>\n      <b>Overall Survival Findings from KEYNOTE-010<\/b>\n    <\/p>\n<p>\n      The Phase 2\/3 KEYNOTE-010 study included 1,034 patients with advanced<br \/>\n      NSCLC with PD-L1 expression (TPS of 1% or more). Similar findings were<br \/>\n      shown in patients who received the FDA-approved dose of KEYTRUDA<br \/>\n      (pembrolizumab) (2 mg\/kg every three weeks) (n=345) and an<br \/>\n      investigational dose of KEYTRUDA (10 mg\/kg every three weeks) (n=346).<br \/>\n      Both groups of patients who received KEYTRUDA were compared to patients<br \/>\n      who received docetaxel (n=343). PD-L1 expression was assessed by the<br \/>\n      immunohistochemistry companion diagnostic test PD-L1 IHC 22C3 PharmDx,<br \/>\n      made by Dako North America, Inc., an Agilent Technologies Company. The<br \/>\n      findings from KEYNOTE-010 are based on the final study analysis. The<br \/>\n      median follow-up was 13.1 months (IQR, 8.6-17.7).\n    <\/p>\n<p>\n      In the total study population (all levels of PD-L1 expression), both<br \/>\n      doses of KEYTRUDA studied significantly improved OS compared with<br \/>\n      docetaxel. Specifically, KEYTRUDA resulted in a 29 percent improvement<br \/>\n      in OS for the 2 mg\/kg dose (HR 0.71, P=0.0008; 95% CI, 0.58-0.88) and a<br \/>\n      39 percent improvement in OS for the 10 mg\/kg dose (HR 0.61, P&lt;0.0001;<br \/>\n      95% CI, 0.49-0.75), compared to docetaxel. The estimated 1-year OS rates<br \/>\n      for KEYTRUDA were 43.2 percent and 52.3 percent, respectively, compared<br \/>\n      to 34.6 percent for docetaxel. Median OS for KEYTRUDA were 10.4 months<br \/>\n      (95% CI, 9.4-11.9) and 12.7 months (95% CI, 10.0-17.3), respectively,<br \/>\n      compared to 8.5 months for docetaxel (95% CI, 7.5-9.8).\n    <\/p>\n<p>\n      Among patients with higher levels of PD-L1 expression (a TPS score of 50<br \/>\n      percent or greater), OS was superior for both KEYTRUDA doses compared<br \/>\n      with docetaxel. Specifically, KEYTRUDA improved OS by 46 percent for the<br \/>\n      2 mg\/kg dose (HR 0.54, P=0.0002; 95% CI, 0.38-0.77) and by 50 percent<br \/>\n      for the 10 mg\/kg dose (HR 0.50, P&lt;0.0001; 95% CI, 0.36-0.70), compared<br \/>\n      to docetaxel. Median OS for KEYTRUDA (2 mg\/kg and 10 mg\/kg,<br \/>\n      respectively) was 14.9 months (95% CI, 10.4 to not reached) and 17.3<br \/>\n      months (95% CI, 11.8 to not reached), compared to 8.2 months for<br \/>\n      docetaxel (95% CI, 6.4-10.7).\n    <\/p>\n<p>\n      \u201cThis is an exciting time, and studies such as KEYNOTE-010 with KEYTRUDA<br \/>\n      are paving the way to a better understanding of how to identify the<br \/>\n      right medicine for each patient,\u201d said Dr. Roy Herbst, Chief of Medical<br \/>\n      Oncology, Yale Cancer Center and Smilow Cancer Hospital at Yale-New<br \/>\n      Haven. \u201cThese study findings show KEYTRUDA provided superior overall<br \/>\n      survival in patients with advanced lung cancer who had positive PD-L1<br \/>\n      expression, and support its potential in the treatment of this disease.\u201d\n    <\/p>\n<p>\n      <b>Additional Findings from KEYNOTE-010<\/b>\n    <\/p>\n<p>\n      In the total study population, KEYTRUDA (pembrolizumab) prolonged<br \/>\n      progression-free survival (PFS) at both doses, though statistical<br \/>\n      significance was not met (HR 0.88 [95% CI, 0.74-1.05], P=0.07 for 2<br \/>\n      mg\/kg; HR 0.79 [95% CI, 0.66-0.94], P=0.004 for 10 mg\/kg). Among<br \/>\n      patients treated with KEYTRUDA (2 mg\/kg and 10 mg\/kg, respectively),<br \/>\n      median PFS was 3.9 months (95% CI, 3.1-4.1) and 4.0 months (95% CI,<br \/>\n      2.7-4.3), compared to 4.0 months for docetaxel (95% CI, 3.1-4.2).\n    <\/p>\n<p>\n      Patients with higher levels of PD-L1 expression (a TPS score of 50<br \/>\n      percent or greater) who were treated with KEYTRUDA had significantly<br \/>\n      prolonged PFS compared to docetaxel (HR 0.59 [95% CI, 0.44-0.78,<br \/>\n      P=0.0001] for 2 mg\/kg; HR 0.59 [95% CI, 0.45-0.78, P&lt;0.0001] for 10<br \/>\n      mg\/kg). Among patients treated with KEYTRUDA (2 mg\/kg and 10 mg\/kg,<br \/>\n      respectively), median PFS was 5.0 months (95% CI, 4.0-6.5) and 5.2<br \/>\n      months (95% CI, 4.1-8.1), compared to 4.1 months for docetaxel (95% CI,<br \/>\n      3.6-4.3).\n    <\/p>\n<p>\n      Additionally, the safety of KEYTRUDA was consistent with what has been<br \/>\n      seen in previous trials among advanced lung cancer patients. Grade 3-5<br \/>\n      treatment-related adverse events for KEYTRUDA (2 mg\/kg and 10 mg\/kg,<br \/>\n      respectively) included: decreased appetite (n=3, n=1), fatigue (n=4,<br \/>\n      n=6), nausea (n=1, n=2), rash (n=1, n=1), diarrhea (n=2, n=0), asthenia<br \/>\n      (n=1, n=2), stomatitis (n=0, n=1), and anemia (n=3, n=1). The most<br \/>\n      common immune-mediated adverse events for KEYTRUDA (2 mg\/kg and 10<br \/>\n      mg\/kg, respectively) included: hypothyroidism (8% [n=28], 8% [n=28]),<br \/>\n      hyperthyroidism (4% [n=12], 6% [n=20]), and pneumonitis (5% [n=16], 4%<br \/>\n      [n=15]). There were three treatment-related deaths among patients<br \/>\n      receiving KEYTRUDA at the 2 mg\/kg dose (pneumonitis [n=2], pneumonia<br \/>\n      [n=1]) and three treatment-related deaths among patients receiving<br \/>\n      KEYTRUDA at the 10 mg\/kg dose (myocardial infarction [n=1], pneumonia<br \/>\n      [n=1], and pneumonitis [n=1]).\n    <\/p>\n<p>\n      <b>About KEYNOTE-010 and the KEYTRUDA Development Program<\/b>\n    <\/p>\n<p>\n      KEYNOTE-010 is a global, open-label, randomized, pivotal Phase 2\/3 study<br \/>\n      (ClinicalTrials.gov, NCT01905657) evaluating two doses of KEYTRUDA (2<br \/>\n      mg\/kg or 10 mg\/kg every three weeks) compared to docetaxel (75 mg\/m^2<br \/>\n      every three weeks) in 1,034 patients with squamous and non-squamous<br \/>\n      NSCLC who experienced disease progression after platinum-containing<br \/>\n      systemic therapy and whose tumors expressed PD-L1. The primary endpoints<br \/>\n      were OS and PFS. Tumor response was assessed at week 9, then every 9<br \/>\n      weeks thereafter per RECIST 1.1 criteria by independent, central,<br \/>\n      blinded, radiographic review and investigator-assessed, immune-related<br \/>\n      response criteria.\n    <\/p>\n<p>\n      The KEYTRUDA program currently addresses more than 30 tumor types in<br \/>\n      more than 160 clinical trials, including more than 80 combinations of<br \/>\n      KEYTRUDA with other cancer treatments. In lung cancer, KEYTRUDA is being<br \/>\n      studied across lines of therapy, both as a monotherapy and in<br \/>\n      combination with chemotherapy. Registration-enabling trials of KEYTRUDA<br \/>\n      (pembrolizumab) are currently enrolling patients in melanoma, NSCLC,<br \/>\n      head and neck cancer, bladder cancer, gastric cancer, colorectal cancer,<br \/>\n      esophageal cancer, breast cancer, Hodgkin lymphoma, multiple myeloma and<br \/>\n      other tumors, with further trials in planning for other cancers.\n    <\/p>\n<p>\n      <b>About Lung Cancer<\/b>\n    <\/p>\n<p>\n      Lung cancer, which forms in the tissues of the lungs, usually within<br \/>\n      cells lining the air passages, is the leading cause of cancer death<br \/>\n      worldwide. Each year, more people die of lung cancer than die of colon,<br \/>\n      breast, and prostate cancers combined. The two main types of lung cancer<br \/>\n      are non-small-cell and small-cell. NSCLC is the most common type of lung<br \/>\n      cancer, accounting for about 85 percent of all cases. The five-year<br \/>\n      relative survival rate for patients suffering from highly advanced,<br \/>\n      metastatic (Stage IV) lung cancers is estimated to be four percent.\n    <\/p>\n<p>\n      <b>About KEYTRUDA (pembrolizumab) Injection 100 mg<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is a humanized monoclonal antibody that works by increasing the<br \/>\n      ability of the body\u2019s immune system to help detect and fight tumor<br \/>\n      cells. KEYTRUDA blocks the interaction between PD-1 and its ligands,<br \/>\n      PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both<br \/>\n      tumor cells and healthy cells.\n    <\/p>\n<p>\n      KEYTRUDA is indicated in the United States at a dose of 2 mg\/kg<br \/>\n      administered as an intravenous infusion over 30 minutes every three<br \/>\n      weeks for the treatment of patients with unresectable or metastatic<br \/>\n      melanoma.\n    <\/p>\n<p>\n      KEYTRUDA is also indicated for the treatment of patients with metastatic<br \/>\n      non-small cell lung cancer (NSCLC) whose tumors express PD-L1 as<br \/>\n      determined by an FDA-approved test with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA. The NSCLC<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. An improvement in survival or<br \/>\n      disease-related symptoms has not yet been established. Continued<br \/>\n      approval for this indication may be contingent upon verification and<br \/>\n      description of clinical benefit in the confirmatory trials.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA (pembrolizumab)<\/b>\n    <\/p>\n<p>\n      Immune-mediated pneumonitis occurred in 19 (3.5%) of 550 patients,<br \/>\n      including Grade 2 (1.1%), 3 (1.3%), 4 (0.4%), or 5 (0.2%) pneumonitis.<br \/>\n      Monitor patients for signs and symptoms of pneumonitis. Evaluate<br \/>\n      suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      (pembrolizumab) for Grade 2; permanently discontinue KEYTRUDA for Grade<br \/>\n      3 or 4 or recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      Immune-mediated colitis occurred in 4 (0.7%) of 550 patients, including<br \/>\n      Grade 2 (0.2%) or 3 (0.4%) colitis. Monitor patients for signs and<br \/>\n      symptoms of colitis. Administer corticosteroids for Grade 2 or greater<br \/>\n      colitis. Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue<br \/>\n      KEYTRUDA for Grade 4 colitis.\n    <\/p>\n<p>\n      Immune-mediate hepatitis occurred in patients receiving KEYTRUDA.<br \/>\n      Monitor patients for changes in liver function. Administer<br \/>\n      corticosteroids for Grade 2 or greater hepatitis and, based on severity<br \/>\n      of liver enzyme elevations, withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Hypophysitis occurred in 1 (0.2%) of 550 patients, which was Grade 3 in<br \/>\n      severity. Monitor patients for signs and symptoms of hypophysitis<br \/>\n      (including hypopituitarism and adrenal insufficiency). Administer<br \/>\n      corticosteroids and hormone replacement as clinically indicated.<br \/>\n      Withhold KEYTRUDA for Grade 2; withhold or discontinue for Grade 3 or 4<br \/>\n      hypophysitis.\n    <\/p>\n<p>\n      Hyperthyroidism occurred in 10 (1.8%) of 550 patients, including Grade 2<br \/>\n      (0.7%) or 3 (0.3%). Hypothyroidism occurred in 38 (6.9%) of 550<br \/>\n      patients, including Grade 2 (5.5%) or 3 (0.2%). Thyroid disorders can<br \/>\n      occur at any time during treatment. Monitor patients for changes in<br \/>\n      thyroid function (at the start of treatment, periodically during<br \/>\n      treatment, and as indicated based on clinical evaluation) and for<br \/>\n      clinical signs and symptoms of thyroid disorders. Administer replacement<br \/>\n      hormones for hypothyroidism and manage hyperthyroidism with thionamides<br \/>\n      and beta-blockers as appropriate. Withhold or discontinue KEYTRUDA for<br \/>\n      Grade 3 or Grade 4 hyperthyroidism.\n    <\/p>\n<p>\n      Type 1 diabetes mellitus, including diabetic ketoacidosis, occurred in 3<br \/>\n      (0.1%) of 2117 patients. Monitor patients for hyperglycemia or other<br \/>\n      signs and symptoms of diabetes. Administer insulin for type 1 diabetes,<br \/>\n      and withhold KEYTRUDA and administer anti-hyperglycemics in patients<br \/>\n      with severe hyperglycemia.\n    <\/p>\n<p>\n      Immune-mediated nephritis occurred in patients receiving KEYTRUDA.<br \/>\n      Monitor patients for changes in renal function. Administer<br \/>\n      corticosteroids for Grade 2 or greater nephritis. Withhold KEYTRUDA for<br \/>\n      Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      Other clinically important immune-mediated adverse reactions can occur.<br \/>\n      For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement to Grade 1 or less, initiate<br \/>\n      corticosteroid taper and continue to taper over at least 1 month. Based<br \/>\n      on limited data from clinical studies in patients whose immune-related<br \/>\n      adverse reactions could not be controlled with corticosteroid use,<br \/>\n      administration of other systemic immunosuppressants can be considered.<br \/>\n      Resume KEYTRUDA when the adverse reaction remains at Grade 1 or less<br \/>\n      following steroid taper. Permanently discontinue KEYTRUDA<br \/>\n      (pembrolizumab) for any Grade 3 immune-mediated adverse reaction that<br \/>\n      recurs and for any life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant, immune-mediated adverse reactions<br \/>\n      occurred in less than 1% of 550 patients: rash, vasculitis, hemolytic<br \/>\n      anemia, serum sickness, and myasthenia gravis.\n    <\/p>\n<p>\n      Severe and life-threatening infusion-related reactions have been<br \/>\n      reported in 3 (0.1%) of 2117 patients. Monitor patients for signs and<br \/>\n      symptoms of infusion-related reactions including rigors, chills,<br \/>\n      wheezing, pruritus, flushing, rash, hypotension, hypoxemia, and fever.<br \/>\n      For Grade 3 or 4 reactions, stop infusion and permanently discontinue<br \/>\n      KEYTRUDA.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA was discontinued due to adverse reactions in 14% of 550<br \/>\n      patients. Serious adverse reactions occurred in 38% of patients. The<br \/>\n      most frequent serious adverse reactions reported in at least 2% of<br \/>\n      patients were pleural effusion, pneumonia, dyspnea, pulmonary embolism,<br \/>\n      and pneumonitis. The most common adverse reactions (reported in at least<br \/>\n      20% of patients) were fatigue (44%), cough (29%), decreased appetite<br \/>\n      (25%), and dyspnea (23%)\n    <\/p>\n<p>\n      No formal pharmacokinetic drug interaction studies have been conducted<br \/>\n      with KEYTRUDA. It is not known whether KEYTRUDA is excreted in human<br \/>\n      milk. Because many drugs are excreted in human milk, instruct women to<br \/>\n      discontinue nursing during treatment with KEYTRUDA and for 4 months<br \/>\n      after the final dose.\n    <\/p>\n<p>\n      Safety and effectiveness of KEYTRUDA have not been established in<br \/>\n      pediatric patients.\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck Oncology,<br \/>\n      helping people fight cancer is our passion and supporting accessibility<br \/>\n      to our cancer medicines is our commitment. Our focus is on pursuing<br \/>\n      research in immuno-oncology and we are accelerating every step in the<br \/>\n      journey \u2013 from lab to clinic \u2013 to potentially bring new hope to people<br \/>\n      with cancer. For more information about our oncology clinical trials,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51247483&amp;newsitemid=20151219005003&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=1&amp;md5=ec4e22a02129e51b1179a91ce5a326d2\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global health care leader working to help the world<br \/>\n      be well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to health care through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51247483&amp;newsitemid=20151219005003&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=7090a23de4641e2d2ed273e2a0a44788\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51247483&amp;newsitemid=20151219005003&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=dc2061f79e61a9985bf59e60b514d75c\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51247483&amp;newsitemid=20151219005003&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=311b085a33a126a90b262f037bf8a988\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51247483&amp;newsitemid=20151219005003&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=b0387b3d0e31a2180a962a053901fe2e\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51247483&amp;newsitemid=20151219005003&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=6&amp;md5=ad5d0f58b43afa2889246d74a1471cd1\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the United States Private Securities<br \/>\n      Litigation Reform Act of 1995. These statements are based upon the<br \/>\n      current beliefs and expectations of the company\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2014 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51247483&amp;newsitemid=20151219005003&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=21e30f9419b4c56c55cdbae9b320d340\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51247483&amp;newsitemid=20151219005003&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf+&amp;index=8&amp;md5=39c15bc746dd5c4f7bafcc80bf2a21ab\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<br \/>\n      <\/b><\/a><b>and the Medication Guide for KEYTRUDA at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51247483&amp;newsitemid=20151219005003&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=9&amp;md5=e5144567fb02e8a9d8edb98d8d00cd05\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><\/a>\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20151219005003r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Courtney        Ronaldo, 908-236-1108<br \/>or<br \/>Investors:<br \/>Teri Loxam,        908-740-1986<br \/>or<br \/>Justin Holko, 908-740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from the pivotal KEYNOTE-010 study, the first study of its kind to evaluate the potential of an immunotherapy compared to chemotherapy based on prospective measurement of PD-L1 expression in patients with advanced non-small cell lung cancer (NSCLC). In the Phase 2\/3 study, KEYTRUDA \u00ae (pembrolizumab), Merck\u2019s anti-PD-1 (programmed death receptor-1) therapy, significantly improved overall survival (OS) compared to chemotherapy in patients with any level of PD-L1 expression, as defined by a tumor proportion score (TPS) of 1 percent or more. The results were published in The Lancet and will be presented at the European Society for Medical Oncology (ESMO) Asia 2015 Congress. \u201cBecause lung cancer remains one of the most common and most challenging cancers to treat, understanding the role that KEYTRUDA can play in helping patients was essential to our development program. In this study in patients<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,55,289],"class_list":["post-745055","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Significantly Improves Survival Compared to Chemotherapy in Previously-Treated Patients with Non-Small Cell Lung Cancer Whose Tumors Express Any Level of PD-L1 - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-significantly-improves-survival-compared-to-chemotherapy-in-previously-treated-patients-with-non-small-cell-lung-cancer-whose-tumors-express-any-level-of\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Significantly Improves Survival Compared to Chemotherapy in Previously-Treated Patients with Non-Small Cell Lung Cancer Whose Tumors Express Any Level of PD-L1 - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from the pivotal KEYNOTE-010 study, the first study of its kind to evaluate the potential of an immunotherapy compared to chemotherapy based on prospective measurement of PD-L1 expression in patients with advanced non-small cell lung cancer (NSCLC). In the Phase 2\/3 study, KEYTRUDA \u00ae (pembrolizumab), Merck\u2019s anti-PD-1 (programmed death receptor-1) therapy, significantly improved overall survival (OS) compared to chemotherapy in patients with any level of PD-L1 expression, as defined by a tumor proportion score (TPS) of 1 percent or more. The results were published in The Lancet and will be presented at the European Society for Medical Oncology (ESMO) Asia 2015 Congress. \u201cBecause lung cancer remains one of the most common and most challenging cancers to treat, understanding the role that KEYTRUDA can play in helping patients was essential to our development program. In this study in patients\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-significantly-improves-survival-compared-to-chemotherapy-in-previously-treated-patients-with-non-small-cell-lung-cancer-whose-tumors-express-any-level-of\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:24:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"13 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keytruda-pembrolizumab-significantly-improves-survival-compared-to-chemotherapy-in-previously-treated-patients-with-non-small-cell-lung-cancer-whose-tumors-express-any-level-of\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keytruda-pembrolizumab-significantly-improves-survival-compared-to-chemotherapy-in-previously-treated-patients-with-non-small-cell-lung-cancer-whose-tumors-express-any-level-of\\\/\",\"name\":\"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Significantly Improves Survival Compared to Chemotherapy in Previously-Treated Patients with Non-Small Cell Lung Cancer Whose Tumors Express Any Level of PD-L1 - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2015-12-19T10:55:00+00:00\",\"dateModified\":\"2025-11-07T06:24:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keytruda-pembrolizumab-significantly-improves-survival-compared-to-chemotherapy-in-previously-treated-patients-with-non-small-cell-lung-cancer-whose-tumors-express-any-level-of\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keytruda-pembrolizumab-significantly-improves-survival-compared-to-chemotherapy-in-previously-treated-patients-with-non-small-cell-lung-cancer-whose-tumors-express-any-level-of\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keytruda-pembrolizumab-significantly-improves-survival-compared-to-chemotherapy-in-previously-treated-patients-with-non-small-cell-lung-cancer-whose-tumors-express-any-level-of\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Significantly Improves Survival Compared to Chemotherapy in Previously-Treated Patients with Non-Small Cell Lung Cancer Whose Tumors Express Any Level of PD-L1\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Significantly Improves Survival Compared to Chemotherapy in Previously-Treated Patients with Non-Small Cell Lung Cancer Whose Tumors Express Any Level of PD-L1 - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-significantly-improves-survival-compared-to-chemotherapy-in-previously-treated-patients-with-non-small-cell-lung-cancer-whose-tumors-express-any-level-of\/","og_locale":"en_US","og_type":"article","og_title":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Significantly Improves Survival Compared to Chemotherapy in Previously-Treated Patients with Non-Small Cell Lung Cancer Whose Tumors Express Any Level of PD-L1 - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from the pivotal KEYNOTE-010 study, the first study of its kind to evaluate the potential of an immunotherapy compared to chemotherapy based on prospective measurement of PD-L1 expression in patients with advanced non-small cell lung cancer (NSCLC). In the Phase 2\/3 study, KEYTRUDA \u00ae (pembrolizumab), Merck\u2019s anti-PD-1 (programmed death receptor-1) therapy, significantly improved overall survival (OS) compared to chemotherapy in patients with any level of PD-L1 expression, as defined by a tumor proportion score (TPS) of 1 percent or more. The results were published in The Lancet and will be presented at the European Society for Medical Oncology (ESMO) Asia 2015 Congress. \u201cBecause lung cancer remains one of the most common and most challenging cancers to treat, understanding the role that KEYTRUDA can play in helping patients was essential to our development program. In this study in patients","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-significantly-improves-survival-compared-to-chemotherapy-in-previously-treated-patients-with-non-small-cell-lung-cancer-whose-tumors-express-any-level-of\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:24:41+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-significantly-improves-survival-compared-to-chemotherapy-in-previously-treated-patients-with-non-small-cell-lung-cancer-whose-tumors-express-any-level-of\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-significantly-improves-survival-compared-to-chemotherapy-in-previously-treated-patients-with-non-small-cell-lung-cancer-whose-tumors-express-any-level-of\/","name":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Significantly Improves Survival Compared to Chemotherapy in Previously-Treated Patients with Non-Small Cell Lung Cancer Whose Tumors Express Any Level of PD-L1 - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2015-12-19T10:55:00+00:00","dateModified":"2025-11-07T06:24:41+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-significantly-improves-survival-compared-to-chemotherapy-in-previously-treated-patients-with-non-small-cell-lung-cancer-whose-tumors-express-any-level-of\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-significantly-improves-survival-compared-to-chemotherapy-in-previously-treated-patients-with-non-small-cell-lung-cancer-whose-tumors-express-any-level-of\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-significantly-improves-survival-compared-to-chemotherapy-in-previously-treated-patients-with-non-small-cell-lung-cancer-whose-tumors-express-any-level-of\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Significantly Improves Survival Compared to Chemotherapy in Previously-Treated Patients with Non-Small Cell Lung Cancer Whose Tumors Express Any Level of PD-L1"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"4947f2ef-c060-4fa3-a2f4-0eaf90bbe391","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improves-Survival-Compared-to-Chemotherapy-in-Previously-Treated-Patients-with-Non-Small--CR5FQ.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745055","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745055\/revisions"}],"predecessor-version":[{"id":3674554,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745055\/revisions\/3674554"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745055"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745055"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}